On May 12, ZBD Pharmaceutical signed a series of strategic cooperation agreements with Shanghai University of Traditional Chinese Medicine...
ZBD issued the "2020 Annual Report ", the company s revenue and net profit increased -- the operating income of 340 4 billion yuan, a year-on-year growth of 34%; Net profit attributable to shareholders of the listed company was 43 6 billion yuan, ...
In the 2020 annual report, the company achieved an operating income of 3 404 billion yuan and a net profit of 436 million yuan for shareholders of the listed company ...
From March 26 to 28, 2021, a training course on external treatment of traditional Chinese medicine and preparation and application of external drugs was held in Luoyang...
Fang Tonghua pays close attention to the development of TCM, and believes that China still has shortcomings in TCM evaluation system, quality control and basic research...
The formulation of a national drug standard for TCM formula granules has been put on the agenda, which will help promote the standardized development of the TCM formula granules industry...
Since the implementation of the Healthy China strategy was put forward, the state has issued a series of documents, promoting the pharmaceutical industry to stand at a new starting point of innovation and development...
The fourth session of the 13th National People s Congress (NPC) opened in Beijing at 9 am on March 5, marking the start of the "two sessions " in China Chairman Fang Tonghua attended the meeting as the representative of Heilongjiang delegation...
ZBD has participated in the major scientific and technological project of "Major New Drug Creation " led by Beijing Children s Hospital The variety of the research is ZBD Compound Qinlan Oral Liquid, and the clinical study has been completed ...
ZBD Company disclosed that it recently received a patent authorization certificate issued by the U S Patent Office for the invention "Andrographolide Modified Compound " The patent term is 20 years ...
ZBD innovative drug tablet ZBD0276 has received a "notice of clinical trial acceptability " issued by the State Medical Products Administration and clinical related work can be reviewed and approved after implementation ...
ZBD signed the Technology Transfer and New Drug Research and Development Contract with Guangzhou Hengguokang Pharmaceutical Technology Co , Ltd , and invested 150 million yuan to introduce HNC042...
ZHENBAODAO Groups Co.,Ltd京ICP备19045728号